Similar articles for PMID: 37181950

Year	Number of Results
2000	1
2003	1
2007	2
2008	1
2009	1
2011	3
2012	2
2013	4
2014	3
2015	7
2016	11
2017	3
2018	7
2019	12
2020	12
2021	21
2022	12
2023	8
2024	0

1

TP53 Signature Can Predict Pathological Response From Neoadjuvant Chemotherapy and Is a Prognostic Factor in Patients With Residual Disease.

Takahashi S, Sasaki K, Ishioka C. Takahashi S, et al. Breast Cancer (Auckl). 2023 May 2;17:11782234231167655. doi: 10.1177/11782234231167655. eCollection 2023. Breast Cancer (Auckl). 2023. PMID: 37181950 Free PMC article.

2

A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy.

Chen Y, Cai H, Chen W, Guan Q, He J, Guo Z, Li J. Chen Y, et al. Front Mol Biosci. 2020 Mar 25;7:34. doi: 10.3389/fmolb.2020.00034. eCollection 2020. Front Mol Biosci. 2020. PMID: 32269999 Free PMC article.

3

A nine-lncRNA signature predicts distant relapse-free survival of HER2-negative breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy.

Sun M, Liu X, Xia L, Chen Y, Kuang L, Gu X, Li T. Sun M, et al. Biochem Pharmacol. 2021 Jul;189:114285. doi: 10.1016/j.bcp.2020.114285. Epub 2020 Oct 15. Biochem Pharmacol. 2021. PMID: 33069665

4

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.

Bonnefoi H, Litière S, Piccart M, MacGrogan G, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Moldovan C, Bodmer A, Zaman K, Cufer T, Campone M, Luporsi E, Malmström P, Werutsky G, Bogaerts J, Bergh J, Cameron DA; EORTC 10994/BIG 1-00 Study investigators. Bonnefoi H, et al. Ann Oncol. 2014 Jun;25(6):1128-36. doi: 10.1093/annonc/mdu118. Epub 2014 Mar 11. Ann Oncol. 2014. PMID: 24618153 Free PMC article. Clinical Trial.

5

Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.

Lehmann BD, Ding Y, Viox DJ, Jiang M, Zheng Y, Liao W, Chen X, Xiang W, Yi Y. Lehmann BD, et al. BMC Cancer. 2015 Mar 26;15:179. doi: 10.1186/s12885-015-1102-7. BMC Cancer. 2015. PMID: 25886164 Free PMC article.

6

TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer.

Wang Y, Xu Y, Chen J, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y. Wang Y, et al. Int J Cancer. 2016 Jan 15;138(2):489-96. doi: 10.1002/ijc.29715. Epub 2015 Aug 13. Int J Cancer. 2016. PMID: 26238069 Free article.

7

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Symmans WF, et al. J Clin Oncol. 2007 Oct 1;25(28):4414-22. doi: 10.1200/JCO.2007.10.6823. Epub 2007 Sep 4. J Clin Oncol. 2007. PMID: 17785706

8

TP53 signature diagnostic system using multiplex reverse transcription-polymerase chain reaction system enables prediction of prognosis of breast cancer patients.

Takahashi S, Fukui T, Nomizu T, Kakugawa Y, Fujishima F, Ishida T, Ohuchi N, Ishioka C. Takahashi S, et al. Breast Cancer. 2021 Nov;28(6):1225-1234. doi: 10.1007/s12282-021-01250-z. Epub 2021 Jul 24. Breast Cancer. 2021. PMID: 34302605 Free PMC article.

9

Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.

Luen SJ, Salgado R, Dieci MV, Vingiani A, Curigliano G, Gould RE, Castaneda C, D'Alfonso T, Sanchez J, Cheng E, Andreopoulou E, Castillo M, Adams S, Demaria S, Symmans WF, Michiels S, Loi S. Luen SJ, et al. Ann Oncol. 2019 Feb 1;30(2):236-242. doi: 10.1093/annonc/mdy547. Ann Oncol. 2019. PMID: 30590484 Free article.

10

EarlyR signature predicts response to neoadjuvant chemotherapy in breast cancer.

Buechler SA, Gökmen-Polar Y, Badve SS. Buechler SA, et al. Breast. 2019 Feb;43:74-80. doi: 10.1016/j.breast.2018.11.006. Epub 2018 Nov 17. Breast. 2019. PMID: 30502641

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year